ALDX Aldeyra Therapeutics Inc.

+0.07  (+1%)
Previous Close 7.69
Open 7.69
Price To Book 2.46
Market Cap 212588498
Shares 27,395,425
Volume 259,009
Short Ratio
Av. Daily Volume 804,644

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced April 2, 2019. Phase 2 data to be presented at ARVO May 1, 2019, 3PM.
ADX-102 - topical ocular reproxalap
Dry eye syndrome
Phase 3 data March 25, 2019 - primary endpoint met.
Reproxalap (ADX-102)
Allergic conjunctivitis
Phase 3 data due 2H 2019.
Noninfectious anterior uveitis
Phase 3 initial data due in 2H 2019.
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated in 2019.
ADX-1612 (ganetespib)
Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
Proliferative vitreoretinopathy (PVR)

Latest News

  1. Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  2. Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
  3. Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
  4. Future Brightens for 2 Small Biotech Stocks
  5. Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today
  6. Aldeyra stock jumps 50 percent after eye allergy trial success
  7. Aldeyra's eye drug meets main goal in late-stage study, shares surge
  8. Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?
  9. Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints
  10. Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
  11. Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
  12. Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock
  13. Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT
  14. Aldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript
  15. Aldeyra Therapeutics Announces Year-End 2018 Financial Results
  16. Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019
  17. Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
  18. Aldeyra Therapeutics to Host 2019 Research & Development Day
  19. Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement